This study investigated the relationship between gene expression and disease based on the expression profiles of tissue-specific genes, with the aim of discovering the candidate genes associated with disease risk as diagnostic markers. The gene-expression profiles of approximately 20,000 genes from 4 anaplastic astrocytomas (AAs), 7 glioblastoma multiformes (GBMs), and 1 nontumor brain (NB) were analyzed by in situ-synthesized 60-mer oligonucleotide microarray. The signal intensity of each feature was measured by laser scanner, and gene expression was quantified as the tumor/NB intensity ratio. Gene expression was defined as having increased or decreased when the ratio was ≥1.5 or ≤0.67, respectively. In comparison with NB, 20 genes showed increased expression, and 32 showed decreased expression in AA, while 20 genes showed increased expression, and 164 showed decreased expression in GBM. This research indicates that changes in expression levels of 4 genes in AA and 6 genes in GBM may be useful diagnostic markers. Quantitative reverse transcription-polymerase chain reaction also supported the microarray results for the 6 selected genes. In conclusion, microarray images of excellent quality are of high data reproducibility using entirely standard procedures, and these genes may be associated with the molecular events leading to AA or GBM. (Journal of Biomolecular Screening 2008:912-921) 
T HERE ARE APPROXIMATELY 40,000 GENES in the human genome, and subsets of those genes are expressed in different cell types and under certain disease conditions. DNA microarray analysis can simultaneously monitor the expression of thousands of genes in a given organism and in a single experiment, the results of which can generate gene-expression fingerprints that show the set of expressed genes and help to identify the role of a gene and its phenotype and physiological function in a particular cell type.
Gliomas are solid tumors of the central nervous system and are extremely challenging in terms of therapeutic management: while these tumors are commonly treated with radiation therapy followed by debulking of the primary lesions by surgery, the prognosis for high-graded gliomas such as glioblastoma multiformes (GBMs) is often relatively poor. Microarray technology and gene-expression analysis are powerful tools that can be used to discover molecular markers for many types of cancer, including gliomas. These molecular markers can then be studied as potential targets for glioma-specific chemotherapy or used as tools to indicate the best course of therapy for the patient.
Anaplastic astrocytoma (AA) patients have an average length of survival of 3 years. 1 AA tumors can occur spontaneously or can arise after neurosurgical resection for primary astrocytoma, as can GBMs. 2 AA tumors have elevated cell proliferation rates and increased blood vessel densities: the blood vessels are physically distorted and have dilated lumens or thickened walls; small and medium-sized blood vessels with neoplastic aggregation become obvious from neuroimaging studies. GBM tumors arise either through anaplastic progression from a lower-grade astrocytoma or de novo, 3 and vascular changes often occur during the transition from AA to GBM. 4 GBM tumors have a heterogeneous profile, showing high mitotic activity, nuclear atypia, microvascular proliferation, and necrosis. After surgical resection, radiation therapy, and chemotherapy, GBM still has a poor prognosis, with a median survival of about 12 months. 1 Global gene-expression patterns can characterize human tissues as normal or abnormal. Several genetic aberrations have been shown to occur during malignant transformation, development, and progression of gliomas, and AA is frequently associated with allelic loss on 9p, 13q, 19q, and 22q, areas that include the CDKN2A (cyclin-dependent kinase inhibitor 2A), CDKN2B (cyclin-dependent kinase inhibitor 2B), and p14 ARF genes at 9p21 and the RB1 (retinoblastoma) gene at 13q14. 2 GBM is associated with the inactivation of key tumor suppressor genes PTEN (phosphatase and tensin homolog), TP53 (tumor protein p53), RB1, CDKN2A, CDKN2B, and p14 ARF , and the amplification of proto-oncogenes EGFR (epidermal growth factor receptor), CDK4 (cyclin-dependent kinase 4), MDM2 (murine double minute 2), and PDGFRA (plateletderived growth factor receptor, alpha polypeptide). 2 These data suggest that the formation of AA and GBM involves the interaction of many genes.
Differentially significant genes are potential disease markers and could become the standard method of classification of malignant gliomas or be used to identify possible therapeutic targets for disease treatment. In order to understand the molecular basis of malignant transformation and the relationship between gene expression and disease, the expression levels of approximately 20,000 genes from 4 AAs, 7 GBMs, and a nontumor brain (NB) tissue were analyzed by oligonucleotide microarray technology. Some interesting and mostly novel candidate genes were identified in this study, and the expression of these genes was associated with the malignant grade of astrocytic glioma.
MATERIALS AND METHODS

Tissue samples
Surgical specimens were used for this study. As a control, 1 sample of gliosis tissue (cerebral cortex of the temporal lobe from 1 epileptic female adult, 24 years old) belonging to NB tissue was used. This control was used in order to perform multimicroarray comparison, where hybridization of a common reference sample simultaneously with each experiment is required. 5 In this study, 4 AAs, 7 GBMs, and 1 gliosis tissue sample were obtained after an informed agreement with patients undergoing tumor resection at the Taipei Veterans General Hospital. The AAs were from 2 females (34 and 51 years old) and 2 males (41 and 61 years old). The GBMs were from 2 females (53 and 56 years old) and 5 males (47, 53, 56, 57, and 66 years old). The major portion of the tumor was fixed with 10% formalin and embedded in paraffin for sectioning, and the rest of the tissue was snap-frozen and stored in liquid nitrogen until RNA extraction. Hematoxylin and eosin staining, immunohistochemical staining, and electron microscopy were performed to histologically review every specimen by 2 neuropathologists (Donald M.T. Ho and S.Y. Kung). All tumors were histologically classified according to the 2000 World Health Organization classification of tumors of the central nervous system. 6
RNA isolation and analysis
Twelve frozen tissues were ground to homogenized powder in liquid nitrogen. Total RNA was extracted from each homogenized tissue and purified using the RNeasy Midi Kit, followed by the use of the RNase-free DNase to eliminate any potential DNA contamination per the manufacturer's protocol (QIAGEN Bioscience, Taipei, Taiwan). The quality and quantity of total RNA were assessed using spectrophotometer readings at 260/280 nm, 1.2% formaldehyde-agarose (FA) gel electrophoresis, and an RNA 6000 Nano Lab-on-a-chip Kit with an Agilent 2100 Bioanalyzer system (Agilent Technologies Inc., Taipei, Taiwan). Total RNA was suspended in nuclease-free water and stored at -80°C for later use in both linear amplification labeling and cDNA synthesis for quantitative reverse transcription-polymerase chain reaction (QRT-PCR).
RNA target labeling and cDNA synthesis
Two aliquots of total RNA (400-500 ng) were amplified to complementary RNA (cRNA) and then labeled with Cyanine-3 (Cy3) CTP or Cyanine-5 (Cy5) CTP (Perkin-Elmer/NEN Life Sciences, Taipei, Taiwan), producing Cy3-or Cy5-cRNA by the Agilent Low RNA Input Fluorescent Linear Amplification Kit, per the manufacturer's protocol (Agilent Technologies), respectively. RNeasy Mini columns (QIAGEN Bioscience) were used to purify labeled cRNA. The concentrations of Cy3and Cy5-labeled cRNA were determined using spectrophotometer readings at 260 nm. Total RNA (1 μg) was used to synthesize first-strand cDNA with SuperScript II Reverse Transcriptase (Invitrogen, Taipei, Taiwan) for QRT-PCR.
Microarray hybridization
Each custom-made in situ-synthesized 60-mer oligonucleotide microarray consisted of controls and 17,086 (Agilent G4110A) or 20,173 (Agilent G4110B) unique human genes sourced from the Incyte's Foundation Database and RefSeq. A 10× control target was used for an additional quality control in the microarray hybridization. Each Cy3-and Cy5-labeled cRNA (0.75 μg), 10× control target (50 μl), RNase-free water, and 25× fragmentation buffer (10 μl) were mixed to 260 μl and incubated at 60 °C for 30 min. Then 250 μl of 2× hybridization buffer was added to the labeled cRNA mixture. The dyeswapped hybridization mixtures with a common reference were cohybridized to 2 independent identical 60-mer oligonucleotide microarrays at 60 °C for 17 h in the hybridization oven and subsequently washed according to Agilent's hybridization and wash protocol (Agilent Technologies). The slides were dried using a nitrogen-filled air gun and immediately scanned on an Agilent Technologies G2565AA Microarray Scanner System at 5 μm resolution.
Data analysis
Scanned output files were inspected visually for hybridization artifacts. The Cy3 and Cy5 signal intensities for each feature were extracted from scanned microarray images using Agilent Feature Extraction version A.7.5.1 software (Agilent Technologies) for Agilent G4110A and G4110B, and the dyenormalized and background-subtracted intensities were exported to text files. Extracted data were further analyzed using GeneSpring ® 6.2 software (Silicon Genetics, Redwood City, CA) with a LOWESS algorithm-intensity-dependent normalization-in order to compensate for nonlinear dye biases. Before the analysis, all the controls were discarded. The cross-gene error model within GeneSpring ® 6.2 software (Silicon Genetics) was utilized to enhance the statistical power of the analysis. Data were presented as a ratio of a brain tumor (AA or GBM) against an NB tissue that functioned as an internal standard to avoid gross errors caused by uneven hybridization, and the mean intensity ratios of genes for AA or GBM against NB were also obtained. The software was also used for advanced statistical evaluations, hierarchical tree clustering analysis, and graphical representation. Onto-Express software (http://vortex.cs.wayne.edu:8080) is able to rapidly and automatically translate a list of differentially expressional genes into functional categories. 7 The functional profiles created by Onto-Express are independent of the methods used to select the input set of genes. Onto-Express constructed functional profiles for the following categories: biological processes, cellular components, and molecular functions.
Differentially expressed genes were selected using a parametric-based test (Welch t-test), adjusting the individual p-value with the Benjamini and Hochberg false-discovery rate multiple-test correction. The 17,086 and 20,173 genes were decided for having differential and significant expression only when they passed the following cut-off criteria, according to the method of Rickman et al. 3 First, those genes with a ratio ≥1.5 as up-regulated genes or ≤ 0.67 as down-regulated genes were considered expressional genes using the GeneSpring ® 6.2 software (Silicon Genetics). Second, only those genes that were flagged as gisPosAndSignif = 1 and risPosAndSignif = 1 by the Agilent Feature Extraction software in both Cy3 and Cy5 channels, respectively, which showed the extraction signal was significantly greater than the background signal, were used for comparison. Third, the above genes with a p-value of <0.05 were considered statistically significant and were used for further analyses. Finally, the genes which passed the above criteria and overlapped independent multimicroarray experiments were identified as differential and significant genes.
QRT-PCR
To check the reliability of the differences in expression detected by profiling analysis using the oligonucleotide microarray, QRT-PCR analysis using the same RNA samples that had served for the microarray analysis was performed. Six genes (IGFBP2 [insulin-like growth factor binding protein 2], CDK4, SPARC [osteonectin], MMP9 [matrix metallopeptidase 9], PRKCZ [protein kinase C, zeta], and YWHAH [tyrosine 3-monooxygenase/ tryptophan 5-monooxygenase activation protein, eta polypeptide]) and 1 housekeeping gene GAPDH (glyceraldehyde-3phosphate dehydrogenase) were chosen for the validation. IGFPB2, 8 CDK4, 3 SPARC, 9 and MMP9 10 are frequently found to be overexpressed in human gliomas, while PRKCZ and YWHAH were down-regulated in GBM according to the microarray analysis. PRKCZ is an endogenous stabilizer against oxidative injury and is associated with type 2 diabetes in the Han population in North China, and YWHAH encodes a proapoptotic or antiapoptotic protein. 11, 12 The relative amounts of IGFBP2, CDK4, SPARC, MMP9, PRKCZ, YWHAH, and GAPDH (normalization standard) for 3 AAs, 3 GBMs, and the NB were validated with SYBR Green PCR Master Mix (cat. no. 4309155, Applied Biosystems, Taipei, Taiwan) on an ABI PRISM ® 7000 Sequence Detection System (Applied Biosystems). All primer sequences were input into BLAST (Basic Local Alignment Search Tool, http://www.ncbi.nlm.nih.gov/BLAST/) to make a search for nearly exact matches in order to avoid nonspecific binding ( Table 1) . Each primer pair was run using a matrix of forward and reverse primer concentrations (50, 100, 150, 200, and 250 nM), and threshold cycle measurements were compared with dissociation curves to determine optimal primer concentrations with high amplicon specificity. Triplicate QRT-PCRs were performed in 96-well plates for each gene in a volume of 25 μl containing 0.52 μl of cDNA (25 ng) from reverse transcription, 12.5 μl of 2× SYBR Green PCR Master Mix, 200 nM (2.5 μl) or 250 nM (3.13 μl) forward and reverse primers, and water. The PCR conditions were the initial step of 2 min at 50 °C, with denaturation at 95 °C for 10 min, followed by 40 thermal cycles of denaturation (15 s at 95 °C) and elongation (1 min at 60 °C or 65 °C); a final soak at 4 °C was also incorporated. Results were analyzed with the ABI PRISM 7000 SDS software (version 1.1, Applied Biosystems) and then exported as text-format files into a Microsoft ® Excel 2002 spreadsheet (Redmond, WA) for further analyses. To measure the relative quantity of 2 genes in a given RNA sample, the amplification value derived from the first sequence (IGFBP2/CDK4/SPARC/MMP9/PRKCZ/YWHAH) was divided by the amplification value from the second sequence (GAPDH). The expression ratio of QRT-PCR was calculated for each sample pair (AA or GBM against NB). In order to compare the measured expression data derived from the microarray analysis with the QRT-PCR analysis, each data set was scaled by dividing by the log 2 (mean intensity ratio) of the microarray analysis value by the log 2 of the QRT-PCR analysis value for a given gene.
RESULTS
RNA quality
The quality of the total RNA reached the standard required by the microarray facility at National Yang-Ming University. The following 3 results show the high quality and intact total RNA: 1) the ratio of 260/280 nm for total RNA was 1.8 to 2.0; 2) the FA gel electrophoresis of the total RNA showed sharp, clear 28S and 18S ribosomal RNA (rRNA) bands with none to minimal evidence of total RNA degradation; and 3) the Agilent 2100 Bioanalyzer showed that the ratio of 28S/18S rRNA was typically 1.8 to 2.1.
Data analysis
The 10× control target was clearly visible and was also used to test the reproducibility of the microarray experiments, which was good. Each experiment consisted of 5 replicate microarray hybridizations with the gliosis control (labeled with Cy3) and GBM (labeled with Cy5), all from the same RNA samples. The reproducibility was >80% for global gene expression. Figure 1 shows an illustration depicting the distribution of the log (intensity ratio) for 5 repeats of microarray hybridization. The distribution of the expression of 20,173 genes is extremely consistent, demonstrating that microarrays are a high-throughput and reproducible technology.
Two cRNA (targets) were "dye-swapped" and hybridized to produce 1 microarray with the Cy3-labeled gliosis control/ Cy5-labeled tumor and 1 with the Cy5-labeled gliosis control/ Cy3-labeled tumor. Dye swapping counteracts any dye biases, as well as a measurement of variability between targets and hybridizations from the same RNA sample (technical replicates). 13 The global gene-expression patterns were analyzed by hierarchical tree clustering of the 17,086 and 20,173 genes, looking at GBM relative to NB control (Fig. 2) . These dendrograms allow visualization of the underlying similarities and dissimilarities between the samples. The samples derived from tumors that were diagnosed as GBM are clustered closely with samples derived from tumors from different patients ( Fig. 2A,  2B) . Figure 2C shows tree clustering within the same sample compared to a different sample and demonstrates how closely related the expression profiles are between samples.
To determine whether AA and GBM have distinct gene-expression signatures and to define a logical relationship between gene and disease, GeneSpring ® 6.2 software (Silicon Genetics) was used according to the above criteria described in Materials and Methods. The expression of the commonly present 17,086 genes was analyzed in both Agilent G4110A and G4110B chips for 4 AAs, 7 GBMs, and an NB tissue. Some genes consistently exhibited substantial differential expression in both AA and GBM. EGR1 (early growth response 1), HBB (hemoglobin, beta), HBA1 (hemoglobin, alpha 1), and SPARC were up-regulated in both AA and GBM. DKFZp761H039, NRGN (neurogranin), UCHL1 (ubiquitin carboxyl-terminal esterase L1), SH3GL2 (SH3-domain GRB2-like 2), SNAP25 (synaptosomal-associated protein 25 kDa), BASP1 (brain abundant, membrane attached signal protein 1), ENC1 (ectodermal-neural cortex 1), KIAA0672, C20orf103, CA11 (carbonic anhydrase XI), SYNPR (synaptoporin), B3GNT6 (UDP-GlcNAc: betaGal beta-1,3-N-acetylglucosaminyl-transferase 6), and CDKN2D (cyclin-dependent kinase inhibitor 2D) were down-regulated in both AA and GBM. These genes may be the most abundantly expressed in AA and GBM and play complex and diverse roles in the central nervous system. In AA alone, the expression of 52 genes showed changes; 20 genes had 2.13-to 133.93-fold expression, and 32 genes had 0.21-to 0.52-fold expression ( Table  2 ). In GBM, the expression of 184 genes showed changes; 20 genes had 2.45-to 35.51-fold expression, and 164 genes had 0.04-to 0.48-fold expression ( Table 3) . Of these up-and down-regulated genes, the ones whose functions were most responsive were also classified by Onto-Express. The following are 3 of the genes upregulated in AA and their functions: 1) CKLF (chemokine-like factor) is involved with cell proliferation; 2) LGALS1 (lectin, galactoside-binding, soluble, 1) with apoptosis; and 3) TNC (tenascin C) with cell adhesion. TGFBI (transforming growth factor beta induced), up-regulated in GBM, participates in cell proliferation and negative regulation of cell adhesion.
The following are 4 genes down-regulated in AA and their functions: 1) CDKN2D is involved with cell cycle arrest; 2) MOAP1 (modulator of apoptosis 1) with apoptosis; 3) PLK2 (polo-like kinase 2) with the cell cycle; and 4) ICAM5 (intercellular adhesion molecule 5) with cell-to-cell adhesion. The following are 19 genes down-regulated in GBM and their functions: 1) RTN4 (reticulon 4) and MTCH1 (mitochondrial carrier homolog 1) are involved with the positive regulation of apoptosis; 2) MAPK8IP2 (mitogen-activated protein kinase 8 interacting protein 2), SNCA (synuclein, alpha), and YWHAH with antiapoptosis; 3) CDKN2D with cell cycle arrest; 4) APP (amyloid beta A4 precursor protein) with apoptosis and cell adhesion; 5) TU3A (TU3A protein) and NDRG4 (NDRG family member 4) with the regulation of cell growth; 6) ARNT2 (aryl-hydrocarbon receptor nuclear translocator 2) with hypoxia; 7) CDH18 (cadherin 18, type 2), NRXN3 (neurexin 3-alpha), and NELL2 (neural epidermal growth factor-like 2) with cell adhesion; 8) OPTN (optineurin) with cell death; 9) RASD1 (RAS, dexamethasoneinduced 1) and STMN1 (stathmin 1/oncoprotein 18) with cell growth and/or maintenance; 10) PALM (paralemmin) with cell motility and cellular morphogenesis; 11) ADRA1B (adrenergic, alpha-1B, receptor) with cell-to-cell signaling; and 12) KCNC1 (potassium voltage-gated channel, shaw-related subfamily, member 1) with cell differentiation. The above genes could be involved in the generation and regulation of either AA or GBM.
QRT-PCR analysis
QRT-PCR data more closely matched microarray data (Fig.  3A, 3B) . Clearly, the gene-expression patterns from sample to sample seen for the microarray parallel the pattern observed by
FIG. 2.
Hierarchical tree clustering analyses based on the expressions of 17,086 genes (A) and 20,173 genes (B and C) that differed from GBM and NB. The tissue samples in the tree were joined by very short branches if they had gene-expression patterns that were very similar to each other and by increasingly longer branches as their similarity decreased. Each row is a single gene, and each column in each respective clustering is a tissue sample. GBM1-3, GBM2-3, GBM3-3, GBM4-3, GBM5-3, and GBM6-3 represent the first, second, third, fourth, fifth, and sixth GBM, respectively, with the Cy3-labeled gliosis (NB) and the Cy5-labeled GBM for the microarray experiments. GBM1-5, GBM2-5, GBM3-5, GBM4-5, GBM5-5, GBM6-5, and GBM7-5 represent the first, second, third, fourth, fifth, sixth, and seventh GBM, respectively, with the Cy5-labeled gliosis (NB) and the Cy3-labeled GBM for the microarray experiments. 1GBM7-3, 2GBM7-3, 3GBM7-3, 4GBM7-3, and 5GBM7-3 represent the first, second, third, fourth, and fifth microarray experiment, respectively, with the Cy3-labeled gliosis (NB) and the Cy5-labeled GBM, which came from the same RNA source of the same gliosis (NB) and the seventh GBM, respectively. the QRT-PCR ( Fig. 3C-H) . The minimum and maximum Pearson correlation coefficients (r) of these 6 genes among AA and GBM relative to NB are 0.52 (YWHAH) and 0.96 (IGFBP2), respectively. There is a significant correlation (r = 0.90) between log 2 values determined by microarrays and QRT-PCR for these 6 genes (Fig. 4) . However, the microarrays appeared to underestimate differences in expression relative to QRT-PCR (slope = 1.49). The underestimation of gene-expression differences is likely to be a result of the kinetic difference between a hybridization reaction and a PCR reaction. 13 Correlation between the 2 methods was large for most genes measured, which generally validated that microarray analyses from the current array were statistically reliable and accurate.
DISCUSSION
The success of microarray experiments is dependent on the quality and quantity of the initial RNA sample. In addition, the purchase of these tissue samples is impeded somewhat by the lack of readily available, high-quality, and snap-frozen clinical specimens. The sample size for each group is relatively small because the tissues were collected for 3 years according to the experimental design, and undoubtedly among the most important factors is the amount of RNA degradation that occurred between the time of procurement and preservation of the sample. Because of the above limitations, this research was divided into 2 periods to complete microarray experiments on Agilent G4110A and G4110B chips, respectively. The inclusion of the dye-swapped experiment meant that 2 microarray experiments were performed for 1 sample pair, and the number of the experimental samples was increased twice to solve the problem of the sample size. The additional amplification procedure is very important if the total RNA obtained from a sample is <1 μg. Although an abundant amount of total RNA can be obtained from whole tissue specimens, it is uncertain whether every sample still can yield a sufficient amount of total RNA for the microarray experiment without the additional amplification step. All RNA samples were subjected to an amplification protocol before each labeling step.
The 2 types of chip were chosen to maximize the novelty and significance of the study because AA and GBM have not been very widely researched on Agilent G4110A and G4110B arrays. There are no such articles in Taiwan; therefore this study may discover new genes for AA or GBM. The 2 arrays . 3. Comparison of gene-expression analysis by microarray and QRT-PCR for 6 genes that had up-regulated (IGFBP2, CDK4, SPARC, and MMP9) or down-regulated (PRKCZ and YWHAH) expression in 3 AAs and 3 GBMs relative to NB. The amplification ratio obtained from the QRT-PCR assay and normalized intensity ratio obtained from the microarray were scaled with log 2 for each given gene. (A and B) The log 2 for AA and GBM relative to NB is plotted for the assays of 6 genes. (C-H) The comparison of the individually scaled log 2 obtained from each of the 6 genes is plotted using the assays of 6 tumors. At the top part of each graph, the r is for both assays. AA1, AA2, and AA3 are the first, second, and third AA, respectively. GBM1, GBM2, and GBM3 are the first, second, and third GBM, respectively. with 60-mer oligonucleotide probes are designed to span conserved exons across the transcripts of the targeted full-length genes. This design method gives the maximum confidence in data quality and prevents redundancy in gene coverage.
Gene-Expression Profile of Glioma
The designated significant gene expressions that are ≥1.5fold or ≤0.67-fold in mean intensity ratio, filtering by flag = 2 and p-value <0.05, may have clinical relevance. To identify correlations between these genes and AA/GBM, these significant genes were researched using currently available literature and published reports detailing expression patterns that had previously been associated with gliomas or other types of tumor. The findings are as follows.
H3F3B (H3 histone, family 3B), PTPRZ1 (protein tyrosine phosphatase, receptor-type, Z polypeptide 1), and TNC are upregulated in AA. H3F3B is a member of the histone H3 family and functions as a replacement histone that is synthesized in the absence of DNA replication. H3F3B was identified as a potential tumor suppressor gene, as a mutation in its 3′UTR was found in ovarian tumors. 14 H3F3B may also be involved in DNA replication in AA. PTPRZ1 is involved in cell adhesion and neuronal migration and is likely to be expressed during development of the nervous system. Both the protein and transcript of PTPRZ1 are overexpressed in glioblastoma cells, providing the novel function of the regulation of glioblastoma cell motility. 15 PTPRZ1 is overexpressed in AA but not GBM. This result points to PTPRZ1 as a target for the therapeutic treatment of AA. TNC is a multidomain extracellular matrix glycoprotein. Its gene expression has been shown to be increased in synovial fibroblasts, colorectal carcinoma, and osteosarcoma metastases. [16] [17] [18] TNC could play a clinical role in astrocytoma invasion, gliomagenesis, cell motility, proliferation, and the neoplastic transformation of AA. 19 BEX2 (brain-expressed X-linked 2), MYCBP2 (MYC binding protein 2), and ENTPD6 (ectonucleoside triphosphate diphosphohydrolase 6) are down-regulated in AA. BEX2 is highly expressed in the pituitary, cerebellum, and temporal lobe. 20 A previous study showed that BEX2 was silenced in all tumor specimens examined and exhibited extensive promoter hypermethylation. Reactivation led to increased sensitivity to chemotherapy in a glioma cell line. 21 The BEX2-tumor suppressor gene-may be transcriptionally silenced during AA pathogenesis. The protooncogene MYC (v-myc myelocytomatosis viral oncogene homolog [avian]) is associated with the regulation of cellular proliferation, differentiation, and apoptosis, and it is implicated in a variety of human tumors. 22 Because it binds Myc, MYCBP2 may be involved in the regulation and formation of AA. ENTPD6 is a member of the CD39 subfamily of cation-dependent E-type nucleotidases and mediates catabolism of extracellular nucleotides. The decreased expression of ENTPD6 is also found in the malignant transformation of glioma cells and perhaps is an indicator of AA metastasis. 23 RPS2 (ribosomal protein S2), EGR1, SPARC, and HLA-C (major histocompatibility complex, class I, C) are up-regulated in GBM. RPS2 encodes a ribosomal protein that is located in the cytoplasm and is a putative component of the small 40S ribosomal subunit, which may bind RNA. RPS2 expression is up-regulated in high-grade astrocytomas and may be associated with the progression from a low to a high grade. 24 These data are consistent with the findings of this study because RPS2 expression in GBM was much greater than in AA. EGR1 is an "earlyresponse" protein that is a zinc finger transcription factor. Its expression is induced by a wide variety of processes, including mitosis, proliferation, and differentiation. EGR1 is also involved in the hypoxic up-regulation of tissue factor in GBM. 25 The EGR1-tumor suppressor gene-is also expressed more highly in GBM than in AA and may play a precise role in the pathogenesis of GBM. SPARC is a matrix-associated glycoprotein that elicits changes in cell shape, inhibits cell-cycle progression, influences the synthesis of extracellular matrix, regulates cell proliferation and morphogenesis, stimulates angiogenesis, and initiates bone mineralization. SPARC is also strongly expressed in perivascular cells adjacent to GBM vessels and in U87 glioblastoma tumor cells. 26, 27 The microarray data confirm the above reports, showing a significant overexpression of SPARC in GBM and strongly suggesting that SPARC is a potential indicator for GBM. HLA-C is a heavy chain component of an MHC class I molecule that presents antigenic peptides to cytotoxic T lymphocytes. This highly polymorphic gene encodes natural killer cell receptor-inhibitory alleles. HLA-C emerges as an important transplantation antigen and as a receptor for natural FIG. 4 . Microarray experiments were validated by QRT-PCR. A set of 6 genes (IGFBP2, CDK4, SPARC, MMP9, PRKCZ, and YWHAH) was adopted to create representative samples covering fold-changed ranges. The 3 AAs, 3 GBMs, and 1 NB were used for the comparison of the 2 assays. The r of the log 2 was calculated, and a significant difference existed between the microarray and QRT-PCR.
killer cells. 28 HLA-C is up-regulated in GBM; therefore its presence could promote tumorigenesis. TU3A and APP genes are down-regulated in GBM. TU3A is a putative nuclear protein that negatively regulates cell proliferation. Gene expression is reduced in GBM compared to diffuse astrocytomas; therefore, TU3A may be associated with glioma progression. 29 This study supports that hypothesis because TU3A is down-regulated in GBM but not AA. APP is a cell-surface protease inhibitor. Mutations in APP have been implicated in autosomal dominant Alzheimer disease and cerebral amyloid angiopathy. APP is also present in endothelial cells and is associated with the malignant progression of astrocytic tumors. 30 Because little is known about APP expression in GBM, the precise role and significance of APP should be examined further.
The QRT-PCR validation proves the microarray is reliable in research. A high correlation was obtained between the 2 assays for IGFBP2, CDK4, SPARC, MMP9, PRKCZ, and YWHAH expression levels. The significant gene-expression profiles of AA and GBM have important implications for understanding the mechanisms of brain tumorigenesis. In conclusion, different individuals with AA or GBM have a small set of common genes with highly different expression. The changes are due to differences in the cell types. In addition, the differences of age, gender, health, disease progression, and medication may play important roles in gene expression. A selection of genes is associated with the malignant grade of AA and GBM at the mRNA transcriptional expression level. These molecular markers could be used in the diagnosis and treatment of AA and GBM. For example, PTPRZ1 and TNC up-regulation and ENTDP6 down-regulation may indicate the presence and metastasis of AA, whereas down-regulation of BEX2 may imply an AA with resistance to chemotherapy. Up-regulation of SPARC and HLA-C and down-regulation of APP may diagnose GBM, whereas the levels of up-regulation of RPS2 and EGR1 and downregulation of TU3A may reveal an increase in tumor grade or progression from AA to GBM. The clinical application of microarray analysis to AA/GBM diagnosis, prognosis, and therapeutic intervention is a clear goal for the future. This study is useful for improving the understanding of the initiation of AA and GBM at the molecular level.
